Why Are Accenture Shares Trading Higher Today

March 17, 2022Updated: March 17, 2022

Accenture PLC reported second-quarter FY22 revenue growth of 24 percent  year-on-year to $15.05 billion, beating the consensus of $13.44 billion.

New bookings increased 22 percent Y/Y to $19.6 billion. Consulting revenues rose 29 percent Y/Y to $8.32 billion, and Outsourcing revenues increased 19 percent Y/Y to $6.72 billion.

Geographic Market Revenue

North American market revenue grew 26 percent Y/Y to $7.08 billion; European market increased 24 percent Y/Y to $5.01 billion; Growth Markets Revenue rose 22 percent Y/Y to $2.96 billion.

Industry Group Revenue

Communications, Media & Technology segment revenue rose 29 percent Y/Y to $3.19 billion; Financial Services unit revenue increased 21 percent to $2.87 billion; Health & Public Service division revenue expanded 19 percent to $2.69 billion; Products segment revenue rose 30 percent to $4.33 billion; while the Resources unit revenue increased 21 percent to $1.97 billion.

Margin

The operating margin was consistent at 13.7 percent.

EPS of $2.54 beat the consensus of $2.20.

The company generated $2.16 billion in operating cash flow and held $5.5 billion in cash and equivalents.

Dividend

Accenture declared a quarterly dividend of $0.97 per share, up 10 percent Y/Y.

Accenture now looks to return at least $6.5 billion in cash to shareholders versus previously planned $6.3 billion.

Chair and CEO Julie Sweet said, “Our outstanding second-quarter financial performance demonstrates continued strong, broad-based demand across all our markets, services, and industries.”

Guidance

Accenture sees Q3 FY22 revenue of $15.70 billion – $16.15 billion, above the consensus of $13.94 billion.

Accenture raised the FY22 revenue outlook from $60.13 billion – $61.65 billion to $62.66 billion – $63.67 billion, above the consensus of $55 billion.

Accenture raised the FY22 EPS outlook from $10.32 – $10.60 to $10.61 – $10.81, above the consensus of $9.68.

By Anusuya Lahiri

© 2021 The Epoch Times. The Epoch Times does not provide investment advice. All rights reserved.

American Cancer Society Updates Prostate Cancer Screening Guidelines
RELATED
Stocks Steady After Fed Hike, BoE's Turn Next